Revalesio
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1202 E D St, Tacoma, Washington, 98421, ...Phone Number
(253) 922-2600Website
www.revalesio.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Revalesio
Revalesio is a clinical-stage pharmaceutical company dedicated to addressing bioenergetic failure, which underlies various health conditions. Their innovative research focuses on mitochondrial function to correct metabolic imbalances that contribute to brain damage and neurodegenerative diseases. The company's lead candidate, RNS60, aims to enhance recovery from ischemic strokes and improve the quality of life for individuals with neurological disorders. Revalesio's proprietary technology offers potential solutions for a range of acute, chronic, and age-related conditions.Explore more
Revalesio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Revalesio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Revalesio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Revalesio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Revalesio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Revalesio had a recent Job posting/layoffs
Product Launch: Get notified when Revalesio launches new products
Revalesio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Revalesio is spiking on competitors!
Earning: See what the market has to say on Revalesio recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Revalesio
Compare insights from companies similar to Revalesio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Revalesio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Revalesio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Revalesio.
Revalesio financials insights
Gather financial insights about Revalesio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$13.5M
2016
Private Equity
$14M
2020
Debt
$150K
Revalesio Tech Stack
A closer look at the technologies used by Revalesio
Revalesio News & Media
Revalesio to Present Findings from a Post-Hoc Analysis of Phase 2 RESCUE Trial at SVIN 2025, Highlighting RNS60's Potential to Shorten Hospital Stay
ORLANDO, Fla., Nov. 19, 2025 /PRNewswire/ -- Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, announced today that findings from a post hoc analysis of its Phase 2 RESCUE trial will be presented as an oral...Revalesio to Present RNS60 <12-Hour Data from the Phase 2 RESCUE Trial in Acute Ischemic Stroke at World Stroke Congress 2025
TACOMA, Wash., Oct. 21, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company pioneering neuroprotective therapies for neurological disorders, today announced that data from a post hoc analysis of the RESCUE Phase 2 clinical trial of its investigational drug RNS60 will...Revalesio Receives FDA Fast Track Designation for RNS60 for the Treatment of Acute Ischemic Stroke
TACOMA, Wash., July 31, 2025 /PRNewswire/ -- Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to RNS60, its lead...Revalesio Announces Publication of RESCUE Phase 2 Trial Results Evaluating RNS60 as an Adjunctive Therapy for Acute Ischemic Stroke in the Journal Stroke
Trial met primary endpoints of similar rates of serious adverse events (SAEs) and fewer deaths observed with RNS60 versus placebo Statistically significant reduction in infarct growth (brain tissue loss) – a secondary endpoint – in patients treated with RNS60 adjunct to endovascular...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Revalesio
Sign Up For FreeTo access detailed company insights
Revalesio is a clinical-stage pharmaceutical company dedicated to addressing bioenergetic failure, which underlies various health conditions. Their innovative research focuses on mitochondrial function to correct metabolic imbalances that contribute to brain damage and neurodegenerative diseases. The company's lead candidate, RNS60, aims to enhance... Read More
